Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Curr Opin Mol Ther
; 1(3): 372-85, 1999 Jun.
Article
em En
| MEDLINE
| ID: mdl-11713802
ABSTRACT
Antisense oligonucleotides offer the promise of therapeutic effect with few toxic effects, by virtue of their high selectivity. Preclinical studies have provided evidence of antisense effects in vitro and in vivo, and phase I clinical trials have demonstrated safety, feasibility and activity of antisense oligonucleotides for the treatment of cancer. This review summarizes the status of development of three anticancer antisense oligonucleotides from ISIS Pharmaceuticals.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Terapia Genética
/
Oligonucleotídeos Antissenso
/
Neoplasias
Tipo de estudo:
Prognostic_studies
Idioma:
En
Ano de publicação:
1999
Tipo de documento:
Article